Speedy CAR-T cells take on Hard-to-Treat myeloma in first human safety trial
NCT ID NCT06698744
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 21 times
Summary
This early-stage study tests a new type of CAR-T cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy, UF-KURE-BCMA, is made from a simple blood draw and has a shorter manufacturing time than standard CAR-T cells. The main goal is to check safety and find the right dose, with participants monitored for up to 15 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospitals Cleveland Medical Center Seidman Cancer Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.